ClinicalTrials.gov Identifier |
Title |
Study Characteristics |
Primary Outcome Measures |
Responsible Party |
United States |
|
|
|
|
NCT04299152 |
Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |
—Interventional study —Estimated participants: 20 —Study design: parallel |
Determine the number of patients with COVID-19 who were unable to complete SCE therapy (time frame: 4 weeks) |
Tianhe Stem Cell Biotechnologies Inc., China |
NCT04348435 |
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 |
—Interventional study —Estimated participants: 100 —Study design: parallel |
—Incidence of hospitalization for COVID-19 (time frame: week 0 through week 26 [end of study]) —Incidence of symptoms associated with COVID-19 (time frame: week 0 through week 26 [end of study]) |
Hope Biosciences Stem Cell Research Foundation, Sugar Land, TX |
NCT04355728 |
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS) |
—Interventional study —Estimated participants: 12 —Study design: parallel |
—Incidence of prespecified infusion-associated AEs (time frame: day 5) —Incidence of SAEs (time frame: 90 days) |
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL |
NCT04345601 |
Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure: A Pilot Study |
—Interventional study —Estimated participants: 30 —Intervention model: single group |
—Incidence of unexpected AEs (time frame: 28 days post—cell infusion) —Improved oxygen saturations ≥ 93% (time frame: within 7 days of cell infusion) |
Houston Methodist Hospital, Houston, TX |
China |
|
|
|
|
ChiCTR2000031319 |
Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19: a Single-center, Prospective, Randomised Clinical Trial |
—Interventional study —Estimated participants: 20 —Study design: parallel |
… |
Center for Regenerative Medicine, Renmin Hospital of Wuhan University, China |
ChiCTR2000031735 |
Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19) |
—Interventional study —Estimated participants: 20 —Study design: parallel |
Monitoring of AEs within 24 hours after infusion (including infusion-related events and SAEs associated with nonprimary disease) |
Huzhou Central Hospital, Zhejiang, China |
ChiCTR2000031139 |
Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19) |
—Interventional study —Estimated participants: 20 —Study design: sequential |
—Pulmonary function evaluation —Changes in blood gas analysis —Evaluation of activity —Evaluation of dyspnea |
Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital), Wuhan, Hubei, China |
ChiCTR2000030509 |
Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19) |
—Interventional study —Estimated participants: 40 —Study design: parallel |
Time and rate of novel coronavirus become negative |
The First Hospital of Harbin Medical University, Harbin, Heilongjiang, China |
ChiCTR2000030329 |
Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19) |
—Interventional study —Estimated participants: 90 —Study design: parallel |
—Status of immune function —Nucleic acid test is negative —Length of stay in hospital |
The Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, China |
ChiCTR2000030224 |
Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19) |
—Interventional study —Estimated participants: 32 —Study design: parallel |
—Inflammatory biomarkers —Blood routine —Temperature —Lesions of lung seen in CT scan |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China |
ChiCTR2000030173 |
Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration |
—Interventional study —Estimated participants: 60 —Study design: parallel |
—Pulmonary function —Novel coronavirus pneumonic nucleic acid test |
Nanhua Hospital, affiliated with Nanhua University, Hengyang, Hu'nan, China |
ChiCTR2000030088 |
Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) |
—Interventional study —Estimated participants: 40 —Study design: parallel |
—Nucleic acid test for novel coronavirus is negative —CT scan of ground glass shadow disappeared |
The Sixth Medical Center of PLA General Hospital, Beijing, China |
ChiCTR2000030020 |
The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19) |
—Interventional study —Estimated participants: 40 —Study design: sequential |
—Coronavirus nucleic acid markers have negative rate —Inflammation (per chest CT) —Symptoms improved after 4 treatments |
Second Hospital of University of South China, Hengyang, China |
ChiCTR2000029816 |
Clinical Study of Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) |
—Interventional study —Estimated participants: 60 —Study design: parallel |
Time to disease recovery |
Guangzhou Reborn Health Management Consultation Co, Ltd, Guangzhou, Guangdong, China |
ChiCTR2000029812 |
Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP) |
—Interventional study —Estimated participants: 60 —Study design: parallel |
Time to disease recovery |
Guangzhou Reborn Health Management Consultation Co, Ltd, Guangzhou, Guangdong, China |
ChiCTR2000029606 |
Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) |
—Interventional study —Estimated participants: 63 —Study design: parallel |
Mortality in patients |
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China |
ChiCTR2000029580 |
Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial |
—Interventional study —Estimated participants: 70 —Study design: parallel |
Safety |
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China |
ChiCTR2000029572 |
Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled clinical trial |
—Interventionalstudy —Estimated participants: 30 —Study design: parallel |
PSI |
Xiangyang First People's Hospital, Xiangyang, Hubei, China |
ChiCTR2000029569 |
Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial |
—Interventional study —Estimated participants: 30 —Study design: parallel |
PSI |
Xiangyang First People's Hospital, Xiangyang, Hubei, China |
CTR2000030116 |
Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19) |
Interventional study —Estimated participants: 16 —Study design: dose comparison |
Time to leave ventilator on day 28 after receiving MSC infusion |
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China |
ChiCTR2000030484 |
HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19) |
—Interventional study —Estimated participants: 90 —Study design: parallel |
—PaO2/FiO2 or respiratory rate (without oxygen) —Frequency of respiratory exacerbation —Observe physical signs and symptoms and record clinical recovery time —Number and range of lesions indicated by CT and X-ray of lung —Time for cough to become mild or absent —Time for dyspnea to become mild or no dyspnea —Frequency of oxygen inhalation or noninvasive ventilation, frequency of mechanical ventilation —Inflammatory cytokines (eg, CRP/PCT/SAA) —Frequency of SAE |
Hubei Shiyan Taihe Hospital, Shiyan, Hubei, China |
ChiCTR2000030866 |
Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical COVID-19. |
Observational study —Estimated participants: 30 Study design: single arm |
-Oxygenation index (PaO2/FiO2) —Conversion rate from serious to critical patients —Conversion rate and conversion time from critical to serious patients —Mortality in serious and critical patients |
Changsha First Hospital, Changsha, Hu'nan, China |
ChiCTR2000030835 |
Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19) |
—Interventional study —Estimated participants: 20 —Study design:single arm |
NA |
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, He'nan, China |
ChiCTR2000030138 |
Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) |
—Interventional study —Estimated participants: 60 —Study design: parallel |
Clinical index |
Chinese PLA General Hospital, Haidian Distract, Beijing, China |
NCT04302519 |
Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells |
—Interventional study —Estimated participants: 24 Study design: single group |
Disappear time of ground-glass shadow in lungs (time frame: 14 days) |
CAR-T (Shanghai) Biotechnology Co, Ltd, Shanghai, China |
NCT04288102 |
Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination with Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence |
—Interventional study —Estimated participants: 90 —Study design: parallel |
Size of lesion area and severity of pulmonary fibrosis by chest CT (time frame: at baseline, day 6, day 10, day 14, day 28, day 90] |
Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China, and Wuhan Huoshenshan Hospital, Wuhan, Hubei, China |
NCT04273646 |
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19 |
—Interventional study —Estimated participants: 48 —Study design: parallel |
—Pneumonia severity index (time frame: from baseline to 12 weeks after treatment) —Oxygenation index (PaO2/FiO2; time frame: from baseline to 12 weeks after treatment) |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China |
NCT04252118 |
Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19 |
—Interventional study —Estimated participants: 20 —Study design: parallel |
—Size of lesion area by chest radiograph or CT (time frame: at baseline, day 3, day 6, day 10, day 14, day 21, day 28) —Side effects in MSC treatment group (time frame: at baseline, day 3, day 6, day 10, day 14, day 21, day 28, day 90, day 180) |
Beijing 302 Military Hospital of China, Beijing, China |
NCT04269525 |
Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection |
—Interventional study —Estimated participants: 10 —Intervention model: single group |
Oxygenation index (time frame: on day 14 after enrollment) |
Zhongnan Hospital, Wuhan, Hubei, China |
NCT04276987 |
A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia |
—Interventional study —Estimated participants: 30 —Intervention model: single group |
—Time to clinical improvement (time frame: up to 28 days) —AE and SAE (time frame: up to 28 days) |
Ruijin Hospital, Wuhan, China |
NCT04346368 |
Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients with Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial |
—Interventional study —Estimated participants: 20 —Intervention model: Single group |
—AEs in BM-MSC treatment group (time Frame: baseline–6 months) —Changes in oxygenation index (PaO2/FiO2; time frame: baseline, 6hours, day 1, day 3, week 1, week 2, week 4, month 6) |
Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China |
NCT04339660 |
Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia |
—Interventional study —Estimated participants: 30 —Study design: parallel |
—Observe immune function (TNF-α, IL-1β, IL-6, TGF-β, IL-8, PCT, CRP; time frame: within 4 weeks) —Monitor blood oxygen saturation (time frame: within 4 weeks) |
Puren Hospital, affiliated with Wuhan University of Science and Technology, Wuhan, Hubei, China |
NCT04331613 |
Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS) |
—Interventional study —Estimated participants: 09 —Study design: single group |
—AE and SAE (time frame: within 28 days after treatment) —Changes in lung imaging examinations (time frame: within 28 days after treatment) |
Beijing YouAn Hospital, Capital Medical University Beijing, Beijing, China, |
Brazil |
|
|
|
|
NCT04315987 |
Exploratory Clinical Study to Assess the Efficacy of NestCell Mesenchymal Stem Cell to Treat Patients with Severe COVID-19 Pneumonia |
—Interventional study —Estimated participants :66 —Study design: single group |
Change in clinical condition (time frame: 10 days) |
Hospital Vera Cruz Campina Grande, São Paulo, Brazil |
Jordan |
|
|
|
|
NCT04313322 |
Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells |
—Interventional study —Estimated participants: 5 —Intervention model: single group |
—Improvement of clinical symptoms (time frame: 3 weeks) —AEs measured by chest radiograph/CT scan (time frame: 3 weeks) —RT-PCR results of viral RNA turning negative (time frame: 3 weeks) |
Stem Cells Arabia, Amman, Jordan |
France |
|
|
|
|
NCT04333368 |
Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS |
—Interventional study —Estimated participants: 60 —Intervention model: single group |
Respiratory efficacy evaluated by increase in PaO2/FiO2 ratio from baseline to day 7 in experimental group compared with placebo group |
Hôpital Pitié-Salpêtrière—APHP, Paris, France, and Hôpital Européen Georges Pompidou—APHP, Paris, France |
United Kingdom |
|
|
|
|
NCT04349540 |
A Prospective Non-Interventional Study to Evaluate the Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19 Infection |
—Observational study —Estimated participants: 40 —Intervention model: case-only |
… |
Great Ormond Street Hospital, NHS Foundation Trust, London, United Kingdom |
NCT03042143 |
Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (COVID-19) |
—Interventional study —Estimated participants: 75 —Study design: parallel |
—Oxygenation index (time frame: day 7) —Incidence of SAEs (time frame: 28 days) |
Belfast Health and Social Care Trust, Royal Hospitals Belfast, Northern Ireland, United Kingdom |
Spain |
|
|
|
|
NCT04348461 |
Two-treatment, Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19 |
—Interventional study —Estimated participants: 100 —Study design: parallel |
—Efficacy of administration of allogeneic MSCs derived from AT assessed by survival rate (time frame: 28 days) —Safety of administration of allogeneic MSCs derived from AT assessed by AE rate (time frame: 6 months) |
Instituto de Investigación, Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain |
Denmark |
|
|
|
|
NCT04341610 |
Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients with Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study |
—Interventional study —Estimated participants: 40 —Study design: parallel |
Changes in clinical critical treatment index (time frame: day 7 from randomization) |
Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark |